[Inhibitory effect of diethylstilbestrol on clinical strains of Candida albicans susceptible and resistant to azoles]. / Efecto inhibitorio del dietilestilbestrol sobre aislamientos clínicos de Candida albicans sensibles y resistentes a los azoles.

BACKGROUND: Candida albicans is a microorganism frequently involved in several infections; the patient's oral cavity, caries niches or periodontal disease can sometimes be the reservoir.. The fungal resistance to the available treatments, among other reasons, has led to the search for new antifungal alternatives. AIMS: To carry out a comparative study of the in vitro effects of diethylstilboestrol (DES) and fluconazole (FLZ) on the growth of clinical strains of C. albicans. METHODS: Seven strains of C. albicans were used: a) one FLZ-sensitive culture collection strain, ATCC 90028 (ATCC); b) four oral isolates from four oncological patients with periodontal disease (period 8, 9, 10, and 11); and c) two oral isolates from an AIDS patient with oropharyngeal candidiasis: one FLZ- sensitive (2-76), and another FLZ- resistant (12-99). The MIC was evaluated by standard spectrophotometric techniques using the CLSI (M27-A3) guidelines. The inhibitory concentration 50% (IC50) was calculated using functional analysis with the Graph Pad software. RESULTS: DES inhibited the growth of all C. albicans strains, whether sensitive or resistant to FLZ. Experimental data fitted non-linear functions of inhibitor concentration versus response. Minimum inhibitory concentrations (MIC) for DES and FLZ were as follows: 28.18µg/ml and 4.90µg/ml (ATCC); 17.16µg/ml and 3.14µg/ml (period); 27.64µg/ml and 4.22µg/ml (2-76); 6.16µg/ml and 438.19µg/ml (12-99), respectively. CONCLUSIONS: DES showed antifungal activity on all clinical C. albicans strains isolated from patients with dental and medical diseases. It showed the highest potency on the FLZ-resistant isolate.

Effects of tamoxifen on periodontal disease and Candida albicans of patients with breast cancer and other pathologies.

Candida albicans is involved in periodontal disease, which is influenced by sex hormones. AIM: To study the effects of the estrogen antagonist tamoxifen (TAM) on periodontal disease of oncological patients; clinical oral strains of C. albicans. PATIENTS: With periodontitis and breast cancer and other with AIDS were used. MATERIALS & METHODS: Periodontal disease was evaluated by the academy of periodontology procedures and the growth of clinical C. albicans isolates were evaluated by the Clinical and Laboratory Standards Institute techniques. RESULTS: Women who consumed TAM for more than 2 years decreased periodontitis severity. In vitro, TAM inhibited the growth of both fluconazole-sensitive and resistant C. albicans. CONCLUSION: Administered TAM chronically improves periodontal health and has antifungal activity on oral strains isolated from patients with odontologic and medical pathologies.